Basiliximab
| Evidence Level: N/A | Predicted Indications: 0 |
Table of Contents
- Basiliximab
Basiliximab: Known uses and market status in Canada
Summary
The TxGNN model has no candidate with a score of 0.99 or higher for Basiliximab, so there is currently no new predicted indication. The drug’s recorded uses are listed below.
Quick overview
| Item | Content |
|---|---|
| New predicted indications | None (no model candidate scored 0.99 or higher) |
| Known uses recorded for this drug | 2 |
| Evidence level | Not applicable |
| Canada Market Status | Marketed (marketed DINs: 1 of 1) |
| Number of DINs | 1 (marketed: 1) |
Known uses recorded for this drug
Approved (supported by a licence or label)
| Indication | Source |
|---|---|
| graft rejection | licence in another country |
| kidney transplantation | licence in another country |
Related to an approved indication (same disease category)
| Indication | Approved category |
|---|---|
| none | none |
Relations recorded in the knowledge graph (no approval found)
| Indication |
|---|
| none |
Canada Market Information
| Licence | Product | Dosage form | Status |
|---|---|---|---|
| 02242815 | SIMULECT | Valid |
Safety Considerations
Drug Interactions: 69 interactions were identified in the interaction database. Examples by severity:
- Major: adalimumab, baricitinib, certolizumab pegol, BCG live vaccine (tice substrain). These mostly reflect additive immunosuppression and infection risk.
- Moderate: roflumilast, azathioprine, alemtuzumab, anakinra, canakinumab, alefacept, and several vaccines (tetanus toxoid, anthrax, adenovirus, live cholera).
- Minor: zinc salts (acetate, gluconate, sulfate, chloride).
Package insert warnings and contraindications were not available for this report. Please refer to the package insert for these.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.